Camidanlumab tesirine (ADCT-301)

Camidanlumab tesirine (ADCT-301) is an antibody-drug conjugate (ADC) combining Genmab’s HuMax-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. Camidanlumab tesirine targets CD25, which is expressed on a variety of hematological tumors and shows limited expression on normal tissues, which makes it a very attractive target for antibody-payload approaches. Camidanlumab tesirine has the potential to be a first-in-class antibody-drug conjugate for the treatment of CD25-expressing lymphomas and leukemias. Camidanlumab tesirine is in development for lymphoma under an agreement between Genmab and ADC Therapeutics, under which Genmab owns 25% of the product rights.

Back to top

Lymphoma is a type of cancer that starts in the white blood cells (lymphocytes), which are part of the body’s immune system. There are two main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. National Cancer Institute statistics estimate that 8,500 people will be diagnosed with Hodgkin lymphoma and 74,680 people will be diagnosed with non-Hodgkin lymphoma in the United States in 2018.1,2

A Phase I study of camidanlumab tesirine to treat lymphoma is ongoing. For more information, visit clinicaltrials.gov.


1National Cancer Institute. https://seer.cancer.gov/statfacts/html/hodg.html
2National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html


Back to top

Acute myeloid leukemia (AML) begins in the bone marrow and often moves quickly into the blood. It may then spread to other parts of the body including the lymph nodes, liver, spleen and central nervous system1.  The average age of AML patients is 68, with the disease uncommon in people under 452. National Cancer Institute statistics estimate there will be 19,520 new cases of AML in the United States in 2018.3 Camidanlumab tesirine to treat lymphoma is in Phase I development for acute myeloid leukemia. For more information, visit clinicaltrials.gov.


1 American Cancer Society http://www.cancer.org/cancer/leukemia-acutemyeloidaml/overviewguide/leukemia-aml-overview-what-is-aml
2 American Cancer Society http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-key-statistics
3 National Cancer Institute. https://seer.cancer.gov/statfacts/html/amyl.html

 

Back to top

Camidanlumab tesirine is being tested in multiple solid tumors (advanced solid tumors with literature evidence of CD25(+) treg content, head and neck cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, pancreas cancer, bladder cancer, renal cell carcinoma, melanoma, triple-negative breast cancer, ovarian cancer). For more information on studies of camidanlumab tesirine, visit clinicaltrials.gov.


Back to top